ERBB2 and neoplasm: Moreover, emerging clinical studies have started to suggest the combined use of anti-HER2 and anti-estrogen therapies, which could provide a more favorable treatment outcome for this subtype of tumor (Prat and Baselga, 2013; Montemurro et al., 2013).